Wesbanco Bank Inc. boosted its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 8.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 487,707 shares of the biopharmaceutical company’s stock after purchasing an additional 38,337 shares during the period. Bristol-Myers Squibb makes up 1.5% of Wesbanco Bank Inc.’s portfolio, making the stock its 8th largest position. Wesbanco Bank Inc.’s holdings in Bristol-Myers Squibb were worth $27,175,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Tradewinds Capital Management LLC lifted its stake in Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares during the last quarter. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.8% in the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares during the period. American National Bank increased its position in shares of Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 225 shares during the period. BDO Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the second quarter valued at about $123,000. Finally, Proficio Capital Partners LLC increased its position in shares of Bristol-Myers Squibb by 29.6% in the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 504 shares during the period. 69.51% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Shares Bought by Wesbanco Bank Inc.” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/18/bristol-myers-squibb-company-bmy-shares-bought-by-wesbanco-bank-inc.html.
Bristol-Myers Squibb Company (NYSE:BMY) opened at $61.32 on Friday. The stock has a market cap of $101,260.00, a P/E ratio of 20.69, a PEG ratio of 2.42 and a beta of 1.18. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.77 EPS. research analysts forecast that Bristol-Myers Squibb Company will post 2.99 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.54%. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
A number of research firms have issued reports on BMY. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. Jefferies Group LLC restated a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a research report on Thursday, September 28th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $64.93.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.